Stereotaxis (Stereotaxis) ROE %

: -87.24% (As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Stereotaxis's annualized net income for the quarter that ended in Dec. 2023 was $-20.16 Mil. Stereotaxis's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $23.11 Mil. Therefore, Stereotaxis's annualized ROE % for the quarter that ended in Dec. 2023 was -87.24%.

The historical rank and industry rank for Stereotaxis's ROE % or its related term are showing as below:

STXS' s ROE % Range Over the Past 10 Years
Min: -77.05 Med: -26.28 Max: Negative Equity
Current: -77.05

During the past 13 years, Stereotaxis's highest ROE % was Negative Equity%. The lowest was -77.05%. And the median was -26.28%.

STXS's ROE % is ranked worse than
83.87% of 812 companies
in the Medical Devices & Instruments industry
Industry Median: 0.27 vs STXS: -77.05

Stereotaxis ROE % Historical Data

The historical data trend for Stereotaxis's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stereotaxis Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROE %

-25.65

-19.33

-26.91

-51.27

-76.93

Stereotaxis Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROE %																-50.91	-69.87	-70.48	-83.78	-87.24

Competitive Comparison

For the Medical Instruments & Supplies subindustry, Stereotaxis's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Stereotaxis ROE % Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Stereotaxis's ROE % distribution charts can be found below:

* The bar in red indicates where Stereotaxis's ROE % falls into.

Stereotaxis ROE % Calculation

Stereotaxis's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %	=	Net Income (A: Dec. 2023 )	/	( (Total Stockholders Equity (A: Dec. 2022 )	+	Total Stockholders Equity (A: Dec. 2023 ))	/ count )
	=	-20.713	/	( (31.929	+	21.92)	/ 2 )
	=	-20.713	/	26.9245
	=	-76.93 %

Stereotaxis's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %	=	Net Income (Q: Dec. 2023 )	/	( (Total Stockholders Equity (Q: Sep. 2023 )	+	Total Stockholders Equity (Q: Dec. 2023 ))	/ count )
	=	-20.16	/	( (24.298	+	21.92)	/ 2 )
	=	-20.16	/	23.109
	=	-87.24 %

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.

Stereotaxis (AMEX:STXS) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

	ROE %		(Q: Dec. 2023 )
=	Net Income	/	Total Stockholders Equity
=	-20.16	/	23.109
=	(Net Income / Revenue )	*	(Revenue / Total Assets)	*	(Total Assets / Total Stockholders Equity)
=	(-20.16 / 18.26)	*	(18.26 / 43.2185)	*	(43.2185 / 23.109)
=	Net Margin %	*	Asset Turnover	*	Equity Multiplier
=	-110.41 %	*	0.4225	*	1.8702
=	ROA %	*	Equity Multiplier
=	-46.65 %	*	1.8702
=	-87.24 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

	ROE %		(Q: Dec. 2023 )
=	Net Income	/	Total Stockholders Equity
=	-20.16	/	23.109
=	(Net Income / Pre-Tax Income)	*	(Pre-Tax Income / Operating Income)	*	(Operating Income / Revenue)	*	(Revenue / Total Assets)	*	(Total Assets / Total Stockholders Equity)
=	(-20.16 / -20.16)	*	(-20.16 / -21.216)	*	(-21.216 / 18.26)	*	(18.26 / 43.2185)	*	(43.2185 / 23.109)
=	Tax Burden	*	Interest Burden	*	Operating Margin %	*	Asset Turnover	*	Equity Multiplier
=	1	*	0.9502	*	-116.19 %	*	0.4225	*	1.8702
=	-87.24 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
^* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.

Stereotaxis ROE % Related Terms

Thank you for viewing the detailed overview of Stereotaxis's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Stereotaxis (Stereotaxis) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Stereotaxis Inc (AMEX:STXS) » Definitions » ROE %

Comparable Companies

Traded in Other Exchanges

RJR1:Germany

Address

710 North Tucker Boulevard, Suite 110, St. Louis, MO, USA, 63101

Website

https://www.stereotaxis.com

Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service and accessories stream. The company generates the majority of revenue from the United States.

Executives

Paul J Isaac	10 percent owner	530 FIFTH AVENUE, 20TH FLOOR, NEW YORK NY 10036
Myriam Curet	director	1020 KIFER ROAD, SUNNYVALE CA 94086
David Benfer	director	5 SELDEN AVENUE, BRANFORD CT 06404
Kimberly R. Peery	officer: Chief Financial Officer	C/O STEREOTAXIS, INC., 4320 FOREST PARK AVENUE: SUITE 100, ST. LOUIS MO 63108
Kevin M. Barry	officer: Chief Legal Officer & Secretar	4320 FOREST PARK AVENUE, 100, ST. LOUIS MO 63108
Ross B Levin	director	530 FIFTH AVENUE, 20TH FLOOR, NEW YORK NY 10036
Fariba Fischel Ghodsian	10 percent owner	10990 WILSHIRE BOULEVARD, SUITE 1400, LOS ANGELES CA 90024
Dafna Capital Management Llc	10 percent owner	10990 WILSHIRE BOULEVARD, SUITE 1400, LOS ANGELES CA 90024
David Leo Fischel	director	10990 WILSHIRE BOULEVARD, SUITE 1400, LOS ANGELES CA 90024
Arun Swarup Menawat	director	2412 EIGHTH LINE, OAKVILLE A6 L6H6S9
Joe E Kiani	director	4320 FOREST PARK AVENUE, SUITE 100, ST. LOUIS MO 63108
Paul Brathwaite	officer: VP Research & Development	C/O STEREOTAXIS, INC., 4320 FOREST PARK AVENUE, SUITE 100, ST. LOUIS MO 63108
Martin C Stammer	officer: Chief Financial Officer	C/O STEREOTAXIS, INC., 4320 FOREST PARK AVENUE, SUITE 100, ST. LOUIS MO 63108
Nathan Fischel	director	10990 WILSHIRE BOULEVARD, SUITE 1400, LOS ANGELES CA 90024
Duane Desisto	director	C/O INSULET CORPORATION, 9 OAK PARK DRIVE, BEDFORD MA 01730